US FDA approves Amneal Pharmas biosimilar Fylnetra to treat neutropenia
By, Admin1 min read
Share
Amneal Pharmaceuticals, Inc., a fully integrated essential medicines company, announced that the US Food and Drug Administration (FDA) has approved the company
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
